Chiome Bioscience Reports Exercise Status

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on March 2, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

Chiome Bioscience Reports Exercise Status of 23rd Tranche Subscription Rights for February

Source disclosure: March 02, 2026, 13:00 JST Published by Pulse News Wire: March 02, 2026, 13:50 JST Chiome Bioscience Inc. [4583.T] TOKYO, Mar 02 (Pulse News Wire) – Chiome Bioscience Inc. (4583.T) reported the exercise status of its 23rd tranche subscription rights (with adjustment clause) for February 2026. A total of 1,436,200 shares were delivered during the month, representing 10.56% of the total issuance. As of the end of February, there were 10,773,800 shares remaining une